CA
RCKT icon

Corriente Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Corriente Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-88,927
Closed -$2.02M – 17
2019
Q4 		$2.02M Buy
+88,927
New +$1.49M 1.09% 15

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Corriente Advisors's RCKT Position: Q1 2020 in Review

Corriente Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q1 2020, closing a stake of 88,927 shares — an estimated $2.02M sold.

Corriente Advisors first reported a position in RCKT in Q4 2019 and held it in 1 quarter. The position peaked at $2.02M in Q4 2019. 107 funds tracked by Wall St. Rank hold RCKT as of Q1 2020.

  • Corriente Advisors reported no remaining Rocket Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Corriente Advisors sold 88,927 Rocket Pharmaceuticals shares in Q1 2020, an estimated $2.02M.
  • Corriente Advisors first reported a position in Rocket Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Corriente Advisors's Rocket Pharmaceuticals position peaked at $2.02M in Q4 2019.
  • 107 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2020.

Based on Corriente Advisors's 13F filing for Q1 2020, filed 18 May 2020.